• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen is an Amsterdam based biopharmaceutical company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Clinical trials

The first target indication is in the field of rheumatic diseases. Arthrogen has completed GMP production of its lead product and is preparing the start of the first clinical trial.

Development

It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.

For professionals to learn more on our clinical development program, please follow this link….

For patients to learn more on our clinical development program, please follow this link….

Latest news

MARCH 2016
Today, Friday March 11 2016, Caroline Aalbers, PhD, received the Greiner Award at the NVGCT Spring Symposium for her thesis “Gene Therapy for arthritis: progress towards a clinical trial”. The Greiner Award is a yearly awarded prize for the best thesis or publication in gene therapy. Caroline performed her research for the thesis during her employment at Arthrogen, with the founder of Arthrogen Prof. P.P. Tak as her promoter. We would like to congratulate Caroline with this great honor and reward.

Latest publications

Intra-articular etanercept treatment in inflammatory arthritis...

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...